Reverse signaling via CD30 ligand
- PMID: 8871664
Reverse signaling via CD30 ligand
Abstract
CD30 ligand (CD30L), a member of the TNF family, is a type II membrane protein with a C-terminal extracellular domain that is homologous with the extracellular domains of other TNF family members. Also, like most TNF family members, the N-terminal cytoplasmic domain of CD30L is conserved across species, but not between family members, suggesting a possible biological function. Motivated by this observation, we investigated the potential for CD30L, when activated by cross-linking, to directly transduce a signal to the ligand-bearing cell. Cross-linking of CD30L by a mAb or by CD30-Fc fusion protein induced the production of IL-8 by freshly isolated neutrophils. Further, both cross-linking mechanisms produced a rapid oxidative burst. Indirect effects through CD30 were ruled out, since CD30L, but not CD30, is expressed on neutrophils. Expression of CD30L can be induced in peripheral blood T cells by cross-linking the CD3 component of the TCR. Peripheral blood T cells exposed to suboptimal concentrations of anti-CD3 increased metabolic activity, proliferated, and produced IL-6 in response to cross-linking of CD30L. These results indicate that cross-linked CD30L can transduce a signal to the ligand-bearing cell. This "reverse signaling" via CD30L taken together with previously published data concerning other ligands in the TNF family strongly suggest that, as a rule, TNF family members and their cognate receptors signal bidirectionally, blurring the distinction between ligand and receptor.
Similar articles
-
CD30 ligand/CD30 plays a critical role in Th17 differentiation in mice.J Immunol. 2010 Aug 15;185(4):2222-30. doi: 10.4049/jimmunol.1000024. Epub 2010 Jul 16. J Immunol. 2010. PMID: 20639486
-
Expression of CD30 ligand (CD153) on murine activated T cells.Biochem Biophys Res Commun. 1999 Mar 24;256(3):519-26. doi: 10.1006/bbrc.1999.0336. Biochem Biophys Res Commun. 1999. PMID: 10080930
-
A critical role of CD30 ligand/CD30 in controlling inflammatory bowel diseases in mice.Gastroenterology. 2008 Feb;134(2):447-58. doi: 10.1053/j.gastro.2007.11.004. Epub 2007 Nov 4. Gastroenterology. 2008. PMID: 18242212
-
CD30: expression and function in health and disease.Semin Immunol. 1998 Dec;10(6):457-70. doi: 10.1006/smim.1998.0156. Semin Immunol. 1998. PMID: 9826579 Review.
-
Deciphering CD30 ligand biology and its role in humoral immunity.Immunology. 2006 Jun;118(2):143-52. doi: 10.1111/j.1365-2567.2006.02354.x. Immunology. 2006. PMID: 16771849 Free PMC article. Review.
Cited by
-
Reverse Signaling of Tumor Necrosis Factor Superfamily Proteins in Macrophages and Microglia: Superfamily Portrait in the Neuroimmune Interface.Front Immunol. 2019 Feb 19;10:262. doi: 10.3389/fimmu.2019.00262. eCollection 2019. Front Immunol. 2019. PMID: 30838001 Free PMC article. Review.
-
CD30 on extracellular vesicles from malignant Hodgkin cells supports damaging of CD30 ligand-expressing bystander cells with Brentuximab-Vedotin, in vitro.Oncotarget. 2016 May 24;7(21):30523-35. doi: 10.18632/oncotarget.8864. Oncotarget. 2016. PMID: 27105521 Free PMC article.
-
Multicenter proteome-wide Mendelian randomization study identifies causal plasma proteins in melanoma and non-melanoma skin cancers.Commun Biol. 2024 Jul 13;7(1):857. doi: 10.1038/s42003-024-06538-2. Commun Biol. 2024. PMID: 39003418 Free PMC article.
-
CD137L-DCs, Potent Immune-Stimulators-History, Characteristics, and Perspectives.Front Immunol. 2019 Oct 2;10:2216. doi: 10.3389/fimmu.2019.02216. eCollection 2019. Front Immunol. 2019. PMID: 31632390 Free PMC article. Review.
-
CD30 and CD30-Targeted Therapies in Hodgkin Lymphoma and Other B cell Lymphomas.Curr Hematol Malig Rep. 2016 Dec;11(6):480-491. doi: 10.1007/s11899-016-0345-y. Curr Hematol Malig Rep. 2016. PMID: 27613003 Review.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources